A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have a Mutation of the PIK3CA Gene

Trial Profile

A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have a Mutation of the PIK3CA Gene

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Alpelisib (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 29 May 2018 Planned End Date changed from 31 Dec 2018 to 25 Dec 2018.
    • 06 Feb 2018 Planned End Date changed from 1 Jun 2018 to 31 Dec 2018.
    • 06 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top